Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic therapies for hepatocellular carcinoma.

Daniel H Palmer1, Syed A Hussain, Philip J Johnson

  • 1Cancer Research UK Institute for Cancer Studies, Clinical Research Block, University of Birmingham, Birmingham B15 2TA, UK. palmerd@bham.ac.uk

Expert Opinion on Investigational Drugs
|November 30, 2004
PubMed
Summary

Hepatocellular carcinoma (HCC) treatment varies by stage. While early-stage HCC may be cured with surgery, advanced stages often require palliative systemic therapies or chemoembolisation for survival benefits. Novel agents are under investigation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation of Risk Models for Predicting Post-SVR HCC in Real-World Surveillance Across Global Geographic Regions.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Characterization of Patients with Unresectable Hepatocellular Carcinoma in REFLECT Who Achieved Tumor Response or Alpha-Fetoprotein Response When Treated with Lenvatinib.

Liver cancer·2026
Same author

International Survey of Thromboprophylaxis Practices During Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer.

Clinical genitourinary cancer·2026
Same author

Clinical implications and biomarkers in the PACT-21 CASSANDRA trial.

Lancet (London, England)·2026
Same author

A Delphi consensus for implementing genomic testing in unresectable or metastatic urothelial cancer.

BJU international·2026
Same author

Evaluating BCG response in primary and metachronous non-muscle invasive bladder cancer following prior upper tract urothelial cancer: A systematic review and meta-analysis.

Urologic oncology·2026

Area of Science:

  • Hepatology
  • Medical Oncology
  • Gastroenterology

Background:

  • Hepatocellular carcinoma (HCC) is a significant global health concern.
  • A minority of HCC patients are candidates for curative therapies like surgery.
  • The majority present with advanced disease, precluding curative treatment.

Purpose of the Study:

  • To review current systemic treatment strategies for HCC in adjuvant and palliative settings.
  • To summarize evidence for novel therapeutic agents in HCC treatment.
  • To highlight challenges in designing clinical trials for evaluating new HCC therapies.

Main Methods:

  • Literature review of systemic therapies for HCC.
  • Analysis of current treatment approaches for advanced HCC.

Related Experiment Videos

  • Examination of emerging therapeutic agents and clinical trial designs.

    • Main Results:

    • Curative options are limited to early-stage HCC.
    • Chemoembolisation offers modest survival benefits for select advanced HCC patients.
    • Systemic therapies are commonly used for palliative care in advanced HCC.

    Conclusions:

    • Effective treatment for advanced HCC remains a challenge.
    • Novel therapeutic agents show promise but require rigorous clinical evaluation.
    • Optimizing clinical trial design is crucial for advancing HCC treatment.